Thrombosis

Featured Article

Stroke a Major Burden in the HIV Patient Population

Stroke a Major Burden in the HIV Patient Population

Stroke is very important medical comorbidity of HIV that should receive more research and clinical focus.

Latest Features

Latest News

Effect of Warfarin Dose on Patients With HIV And DVT

Effect of Warfarin Dose on Patients With HIV And DVT

Study results were contrary to investigators' hypothesis regarding warfarin dosing in patients with and without HIV.

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.

Surgical Pulmonary Embolectomy Outcomes Not Affected by Thrombus Location

Surgical Pulmonary Embolectomy Outcomes Not Affected by Thrombus Location

Survival rates were high for patients with both central and peripheral pulmonary emboli.

Intracerebral Hemorrhage: Trends in Medical Complications

Intracerebral Hemorrhage: Trends in Medical Complications

After intracerebral hemorrhage, both acute renal failure and deep venous thrombosis have increased.

Acute Ischemic Stroke: Contact Aspiration vs Stent Retriever

Acute Ischemic Stroke: Contact Aspiration vs Stent Retriever

Contact aspiration and stent retriever approaches for mechanical thrombectomy achieved similar efficacy and safety end points.

How Does Pulmonary Embolism Risk Compare After CVT vs DVT?

How Does Pulmonary Embolism Risk Compare After CVT vs DVT?

Pulmonary embolism risk after cerebral venous thromboembolism is significantly lower than after deep vein thromboembolism.

Venous Thromboembolism Risk Increased With Giant Cell Arteritis

Venous Thromboembolism Risk Increased With Giant Cell Arteritis

Patients with giant cell arteritis were more likely to experience venous thromboembolism during the first 3 months following diagnosis.

Is There Clinical Benefit to >3 Month Rivaroxaban Tx for Unprovoked VTE?

Is There Clinical Benefit to >3 Month Rivaroxaban Tx for Unprovoked VTE?

Two studies presented at CHEST 2016 revealed that rivaroxaban lowered the risk of venous thromboembolism without increasing risk of major bleeding.

Low-Dose NOACs Reduce Thromboembolic Events in Nonvalvular AF

Low-Dose NOACs Reduce Thromboembolic Events in Nonvalvular AF

Compared with patients taking warfarin, patients treated with rivaroxaban and dabigatran had significantly lower rates of intracranial hemorrhage, ischemic stroke or systemic, and all-cause mortality.

Characteristics of Transcatheter Heart Valve Thrombosis After TAVR

Characteristics of Transcatheter Heart Valve Thrombosis After TAVR

Study reveals incidence, risk factors, and clinical characteristics of transcatheter aortic heart valve thrombosis after TAVR.

Sign Up for Free e-Newsletters